Mid-term Clinical Outcomes of Robotic-Assisted Reverse Hybrid Coronary Revascularization. A Single Center Experience.
Aleksander Dokollari,Marco Gemelli,Serge Sicouri,William A. Gray,Timothy A. Shapiro,Frank McGeehin,Marwan Badri,Paul Coady,Eric Gnall,Mara Caroline,Amid A. Khan,Massimo Bonacchi,Francesco Cabrucci,Beatrice Bacchi,Bruno Chiarello,Ashish Shah,Aaron Spooner,Nitin Ghorpade,Ali Fatehi Hassanabad,Stephanie Kjelstrom,Georgia Montone,Mary Ann Wertan,Basel Ramlawi,Francis P. Sutter
DOI: https://doi.org/10.1016/j.amjcard.2023.12.054
IF: 3.133
2024-01-07
The American Journal of Cardiology
Abstract:BACKGROUND Outcomes of robotic-assisted reverse hybrid coronary revascularization (HCR) remain hindered. We aim to analyze mid-term clinical outcomes of robotic-assisted reverse HCR. METHODS All consecutive 285 patients that underwent reverse robotic-assisted HCR between 09/2005-07/2021 are included. Reverse HCR consists of percutaneous coronary intervention (PCI) with stent implantation in non-left anterior descending (LAD) coronary artery vessels performed within 30-days prior to robotic-assisted left internal thoracic artery (LITA) harvesting and LITA to LAD manual anastomosis through a 4-cm left minithoracotomy. Dual antiplatelet therapy was not interrupted on any patient. RESULTS Preoperatively, mean age was 70.2 (± 11.2) years old. Prior to surgery, a total of 168 patients received 1 stent, 112 patients 2 stents, and 5 patients 3 stents. Intraoperatively, mean OR time was 5.9 (± 1) hours, no case was converted to full sternotomy, while 9 (3.1%) patients received intraoperative blood products transfusions. Postoperatively, a low incidence of stroke 1 (0.3%), reoperation for bleeding 7 (2.4%), blood product transfusions 48 (16.8%), and hospital stay (4.8 days) was observed. At 30-day follow-up, 1 (0.3%) patient underwent PCI with stent on a surgical LITA-LAD anastomosis due to graft failure. Mean follow-up was 4.2-years. Reported mid-term outcomes included all-cause death in 31 patients (10.9%), MACCE in 102/285 (35.9%), nonfatal stroke in 2/285 (0.7%), MI in 17/285 (5.9%), and repeat intervention in 50/285 (17.5%) patients. CONCLUSION This single center study reports effective and safe clinical outcomes at mid-term follow-up of reverse HCR procedures for treatment of multivessel coronary artery disease.
cardiac & cardiovascular systems